Previous close | 8.02 |
Open | 8.18 |
Bid | 7.77 x 100 |
Ask | 7.82 x 300 |
Day's range | 7.50 - 8.28 |
52-week range | 2.74 - 12.00 |
Volume | |
Avg. volume | 1,765,385 |
Market cap | 1.728B |
Beta (5Y monthly) | 1.62 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.48 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.40 |
Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin mice Additional proof-of-concept for the advancement of SC379, Sana’s pluripotent stem cell-derived glial progenitor cell product candidate SEATTLE, May 21, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today highlighted that Nature Biotechnology has published a paper titled “You
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Aligns with Analyst Projections Amidst Strategic Clinical Advancements